Edgewise Therapeutics Inc (EWTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.03B
Last updated: Nov 17, 2026 at 11:06 AM ET
Edgewise Therapeutics Inc (EWTX) Earnings: Report Dates and Results
Edgewise Therapeutics (EWTX) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Edgewise Therapeutics reported EPS of $0.84, above the -$0.55 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
EWTX has an expected report date of Feb 24, 2027.
Earnings History
Of the 23 quarters below that had an estimate, EWTX beat 11, missed 10 and matched 2. The widest gap in the table came in the quarter ended Sep 30, 2026, when EPS landed 252.73% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.84 | -$0.55 | -$0.64 - $11.45 | +252.73% | Beat | N/A | 11 | 1 up, 4 down | Nov 4, 2026 |
| Jun 30, 2026 | -$0.53 | -$0.48 | -$0.58 - -$0.40 | -10.42% | Miss | N/A | 12 | 1 up, 1 down | Aug 6, 2026 |
| Mar 31, 2026 | -$0.46 | -$0.48 | -$0.58 - -$0.43 | +4.17% | Beat | N/A | 10 | 0 up, 5 down | May 7, 2026 |
| Dec 31, 2025 | -$0.47 | -$0.43 | -$0.50 - -$0.38 | -9.30% | Miss | N/A | 10 | 3 up, 2 down | Feb 26, 2026 |
| Sep 30, 2025 | -$0.39 | -$0.40 | -$0.44 - -$0.37 | +2.50% | Beat | N/A | 12 | 7 up, 0 down | Nov 6, 2025 |
| Jun 30, 2025 | -$0.34 | -$0.42 | -$0.48 - -$0.38 | +19.05% | Beat | N/A | 12 | 5 up, 1 down | Aug 7, 2025 |
| Mar 31, 2025 | -$0.43 | -$0.42 | -$0.51 - -$0.36 | -2.38% | Miss | N/A | 9 | N/A | May 8, 2025 |
| Dec 31, 2024 | -$0.42 | -$0.42 | -$0.59 - -$0.37 | +0.52% | Beat | N/A | 8 | 1 up, 4 down | Mar 3, 2025 |
| Sep 30, 2024 | -$0.36 | -$0.37 | -$0.41 - -$0.34 | +2.70% | Beat | N/A | 7 | 0 up, 0 down | Nov 7, 2024 |
| Jun 30, 2024 | -$0.34 | -$0.34 | -$0.41 - -$0.31 | 0.00% | In line | N/A | 7 | 0 up, 0 down | Aug 8, 2024 |
| Mar 31, 2024 | -$0.33 | -$0.41 | -$0.49 - -$0.28 | +19.51% | Beat | N/A | 5 | 0 up, 0 down | May 9, 2024 |
| Dec 31, 2023 | -$0.47 | -$0.43 | -$0.50 - -$0.39 | -9.30% | Miss | N/A | 5 | 1 up, 0 down | Feb 22, 2024 |
| Sep 30, 2023 | -$0.41 | -$0.40 | -$0.48 - -$0.34 | -2.50% | Miss | N/A | 5 | 0 up, 0 down | Nov 9, 2023 |
| Jun 30, 2023 | -$0.34 | -$0.40 | -$0.45 - -$0.37 | +15.00% | Beat | N/A | 5 | 0 up, 0 down | Aug 10, 2023 |
| Mar 31, 2023 | -$0.36 | -$0.35 | -$0.38 - -$0.32 | -2.86% | Miss | N/A | 6 | 0 up, 0 down | May 11, 2023 |
| Dec 31, 2022 | -$0.31 | -$0.33 | -$0.39 - -$0.30 | +6.06% | Beat | N/A | 5 | 0 up, 0 down | Feb 23, 2023 |
| Sep 30, 2022 | -$0.34 | -$0.36 | -$0.38 - -$0.33 | +5.56% | Beat | N/A | 5 | 1 up, 0 down | Nov 3, 2022 |
| Jun 30, 2022 | -$0.32 | -$0.32 | -$0.36 - -$0.30 | 0.00% | In line | N/A | 5 | 0 up, 0 down | Aug 4, 2022 |
| Mar 31, 2022 | -$0.30 | -$0.28 | -$0.31 - -$0.26 | -7.14% | Miss | N/A | 5 | 0 up, 0 down | May 11, 2022 |
| Dec 31, 2021 | -$0.26 | -$0.25 | -$0.31 - -$0.16 | -4.00% | Miss | N/A | 4 | N/A | Feb 24, 2022 |
| Sep 30, 2021 | -$0.26 | -$0.24 | -$0.24 - -$0.20 | -8.33% | Miss | N/A | 3 | N/A | Nov 10, 2021 |
| Jun 30, 2021 | -$0.21 | -$0.17 | -$0.20 - -$0.16 | -23.53% | Miss | N/A | 4 | N/A | Aug 9, 2021 |
| Mar 31, 2021 | -$0.14 | -$0.15 | N/A | +6.67% | Beat | N/A | N/A | N/A | May 13, 2021 |
| Dec 31, 2020 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Mar 26, 2021 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.63, after -$1.45 the year before. It was -$0.87 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years below with reported EPS.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.63 | N/A |
| Dec 31, 2024 | -$1.45 | N/A |
| Dec 31, 2023 | -$1.58 | N/A |
| Dec 31, 2022 | -$1.27 | N/A |
| Dec 31, 2021 | -$0.87 | N/A |
| Dec 31, 2020 | Not reported | N/A |
Frequently Asked Questions About EWTX
When is Edgewise Therapeutics's next earnings date?
Edgewise Therapeutics's next earnings report is expected for Feb 24, 2027.
Did EWTX beat earnings estimates last quarter?
Yes. Edgewise Therapeutics reported EPS of $0.84 for the quarter ended Sep 30, 2026, above the -$0.55 estimate, a 252.73% surprise.
What EPS do analysts expect from EWTX next quarter?
The consensus EPS estimate for Edgewise Therapeutics for the quarter ending Dec 31, 2026 is -$0.52 from 15 analysts, with estimates from -$0.76 to -$0.14.
How often does EWTX beat earnings estimates?
Edgewise Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +32.11%.
EWTX pages: Overview, Earnings, Forecast, Financials, Competitors